Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CD228V directed Antibody Drug Conjugate

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

CD228V directed Antibody Drug Conjugate

PF-08046031 | CD228V is an investigational compound. Its safety and efficacy have not been established

Share to an HCP

Overview + Rationale

RATIONALE FOR CANCER TARGET

  • CD228 is highly expressed in multiple MMAE-sensitive tumor types1​
  • CD228 has possible role in tumor proliferation and migration; limited expression in normal tissues by IHC

 

OVERVIEW2

PF-08046031 is an investigational ADC composed of a humanized IgG1 anti-CD228 monoclonal antibody, hL49, conjugated to an average of 4 molecules of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease cleavable valine citrulline linker system (vedotin).

Mechanism of Action

Stage of Development

Melanoma

Advanced Melanoma

Phase 1 Monotherapy
Other

Advanced Solid Tumors

Phase 1 Monotherapy
This information is current as of August 5th 2025.

REFERENCES:  1. Giraddi R, et al. AACR2025. Poster 2959; 2. Mazahreh R, et al. Mol Cancer Ther. 2023 Apr 3;22(4):421-434. doi: 10.1158/1535-7163.MCT-22-0401. PMID: 36800443; PMCID: PMC10068445l; 3. Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06799533  Accessed July 7, 2025.